Skip to content

Analysis of Gefitinib(Drug) in lung cancer.

Retrospective analysis of efficacy of Gefitinib in Non Small Cell Lung Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/05/008490
Enrollment
350
Registered
2017-05-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Lung Cancer Patients

Interventions

Intervention1: Not Applicable: Not Applicable Control Intervention1: Not Applicable: Not Applicable

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age >= 18 years 2) Patients diagnosed with stage IV NSCLC 3) Patients planned and administered gefitinib as palliative treatment 4) ECOG Performance Status 0-3

Exclusion criteria

Exclusion criteria: 1) Age 2) Patients with lung cancers other than NSCLC 3) Patients with active cancer other than NSCLC

Design outcomes

Primary

MeasureTime frame
Overall Survival in patients of NSCLC on gefitinibTimepoint: At the end of the study

Secondary

MeasureTime frame
1. Progression free survival in patients of NSCLC on gefitinib 2. Toxicities of Gefitinib 3. Quality of life of patients on Gefitinib 4. Factors affecting overall survival of patients receiving gefitinib 5. Response Rate Timepoint: 1. At Disease Progression 2. At every Visit 3. At every follow up visits 4. At the End of last follow up 5. Every 2-3 months

Countries

India

Contacts

Public ContactDr Vibhor Sharma

Tata Memorial Hospital

vibhor81@yahoo.co.in07738519711

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026